<DOC>
	<DOCNO>NCT01642771</DOCNO>
	<brief_summary>Recent clinical study show triple-negative breast cancer patient ( ER-/PR-/HER2- ) may benefit Capecitabine chemotherapy . However , optimum post-operative adjuvant Capecitabine chemotherapy regimen determine Chinese population triple-negative breast cancer . Thus 's necessary conduct multi-center Phase III clinical trial verify efficacy safety Capecitabine treatment triple-negative breast cancer . In study , prospective , randomize , open , multi-center Phase III clinical study conduct compare efficacy safety sequential Docetaxel follow Fluorouracil/Epirubicin/Cyclophosphamide ( FEC ) sequential Docetaxel Capecitabine follow Capecitabine/Epirubicin/Cyclophosphamide ( XEC ) post-operative adjuvant chemotherapy treatment triple-negative breast cancer Chinese population .</brief_summary>
	<brief_title>Comparative Study Two Post-operative Adjuvant Chemotherapy Regimens Treating Triple-negative Breast Cancer</brief_title>
	<detailed_description>Post-operative adjuvant chemotherapy show improve overall survival , delay local relapse reduce distant metastasis multiple large-scale prospective clinical trial . In registry clinical trial Capecitabine conduct O Shaughnessy , reveal combined chemotherapy Capecitabine Docetaxel achieve well outcome compare Docetaxel alone . And significant effect Capecitabine also evidence CHAT trial Trastuzumab/Docetaxel/Capecitabine regimen prove perform great Trastuzumab/Docetaxel regimen . In addition well outcome , Capecitabine also show good tolerance safety profile . In 2009 , Finnish Breast Cancer Group publish study result FinXX clinical trial Lancet Oncology , trial , compare efficacy sequential Docetaxel ( 3 cycle ) follow 3 cycle Fluorouracil/Epirubicin/Cyclophosphamide ( FEC ) sequential Docetaxel Capecitabine ( 3 cycle ) follow 3 cycle Capecitabine/Epirubicin/Cyclophosphamide ( XEC ) lymph positive high-risk lymph negative early-stage breast cancer patient . And result show good outcome TX-XEC regimen . 5-year follow-up analysis trial reveal combined Capecitabine regimen bring significant clinical benefit triple-negative breast cancer patient . Another clinical trial NO1062 release preliminary result comparison AC-T AC-XT regimen show combined Capecitabine regimen significantly improve overall survival effect obvious triple -- negative breast cancer patient . Based result FinXX NO1062 , 's great value optimize combine Capecitabine regimen clarify involved question , whether efficacy Capecitabine relate treatment course , whether Capecitabine combine current standardized chemotherapy sequential therapy . Also , still clear conclusion best post-operative adjuvant chemotherapy triple -- negative breast cancer patient . Especially Chinese population , efficacy safety Capecitabine adjuvant chemotherapy well establish . So 's necessary explore reasonable dosage , safety profile efficacy combine Capecitabine therapy . Based purpose , study hop compare efficacy safety sequential Docetaxel follow Fluorouracil/Epirubicin/Cyclophosphamide ( FEC ) sequential Docetaxel Capecitabine follow Capecitabine/Epirubicin/Cyclophosphamide ( XEC ) post-operative adjuvant chemotherapy treatment triple-negative breast cancer Chinese population .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female age 18 70 year old ; Histological confirm unilateral invasive carcinoma ( pathological type applicable ) ; Newly diagnose condition allow direct surgery without absolute contraindication surgery ; No mass microscopic tumor residue surgery resection ; Initiate adjuvant chemotherapy within 30 day surgery ; Axillary lymph node positive ( include sentinel lymph node positive lymph node positive axillary dissection ) , example , axillary lymph node negative require primary tumor size must great 1cm ; Definite report ER/PR/Her2 receptor show ER/PR/Her2 negative ( specific definition : immunohistochemical detection ER &lt; 10 % tumor cell define ER negative , PR &lt; 10 % positive tumor cell define PRnegative , Her2 0~1+ 2+ determined negative via FISH CISH detect ( amplification ) define Her2 negative ) ; No relevant clinical image evidence metastasis show preoperative examination ( M0 ) ; Without peripheral neuropathy ; ECOG performance score 0 1 ; Postoperative recovery good interval least one week since surgery necessary ; White blood cell count &gt; 4 × 10^9/l , neutrophil count &gt; 2 × 10^9/l , platelet count &gt; 100 × 10^9/l hemoglobin 9g/dl ) ; ASAT ALAT &lt; 1.5 fold upper limit normal value , alkaline phosphatase &lt; 2.5 fold upper limit normal value , total bilirubin &lt; 1.5 fold upper limit normal value ; Serum creatinine &lt; 1.5 fold upper limit normal value ; Women childbearing age take contraception measure treatment ; Cardiac function : echocardiographic examination show LEVF &gt; 50 % ; Informed consent form sign . Bilateral breast cancer carcinoma situ ( DCIS / LCIS ) ; Metastasis location ; Any tumor &gt; T4a ( UICC1987 ) ( accompany skin involvement , lump adhesion fixation , inflammatory breast cancer ) ; Any ER , PR Her2 positive ; Contralateral breast clinically radiologically suspect malignant confirm need biopsy ; Previous neoadjuvant therapy , include chemotherapy , radiotherapy hormone therapy ; Previously suffer malignant tumor ( except basal cell carcinoma cervical carcinoma situ ) , include contralateral breast cancer ; Already enrol clinical trial ; Severe systemic disease and/or uncontrollable infection , unable enrol study LEVF &lt; 50 % ( echocardiography ) ; Suffering severe cardiovascular cerebrovascular disease within six month randomization ( : unstable angina , chronic heart failure , uncontrollable high blood pressure &gt; 150/90mmHg , myocardial infarction brain vascular accident ) ; Known allergic taxane anthracycline agent ; Women childbearing age refuse take contraception measure treatment 8 week completion treatment ; Pregnant breastfeed woman ; Pregnancy test show positive result drug administration enrol study ; With mental illness cognitive impairment , unable understand trial protocol side effect complete trial protocol followup ( systematic evaluation require recruiting study ) ; Without personal freedom independent civil capacity .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Triple-negative Breast Cancer</keyword>
	<keyword>Post-operative adjuvant Chemotherapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fluorouracil</keyword>
</DOC>